Combination targeted therapy in relapsed diffuse large B-cell lymphoma

According to data from a single-center phase 1b/2 trial of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in patients with relapsed or refractory DLBCL, the regimen was associated with durable remissions in patients with specific molecular DLBCL subtypes and had mainly reversible adverse events. Complete responses were seen in 38% of patients and were exclusively in those with non-GCB DLBCL and high-grade B-cell lymphoma with rearrangements of MYC and BCL2 or BCL6 (or both).